Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review

Background Long-term retention of patients in Africa's rapidly expanding antiretroviral therapy (ART) programs for HIV/AIDS is essential for these programs' success but has received relatively little attention. In this paper we present a systematic review of patient retention in ART programs in sub-Saharan Africa. Methods and Findings We searched Medline, other literature databases, conference abstracts, publications archives, and the “gray literature” (project reports available online) between 2000 and 2007 for reports on the proportion of adult patients retained (i.e., remaining in care and on ART) after 6 mo or longer in sub-Saharan African, non-research ART programs, with and without donor support. Estimated retention rates at 6, 12, and 24 mo were calculated and plotted for each program. Retention was also estimated using Kaplan-Meier curves. In sensitivity analyses we considered best-case, worst-case, and midpoint scenarios for retention at 2 y; the best-case scenario assumed no further attrition beyond that reported, while the worst-case scenario assumed that attrition would continue in a linear fashion. We reviewed 32 publications reporting on 33 patient cohorts (74,192 patients, 13 countries). For all studies, the weighted average follow-up period reported was 9.9 mo, after which 77.5% of patients were retained. Loss to follow-up and death accounted for 56% and 40% of attrition, respectively. Weighted mean retention rates as reported were 79.1%, 75.0% and 61.6 % at 6, 12, and 24 mo, respectively. Of those reporting 24 mo of follow-up, the best program retained 85% of patients and the worst retained 46%. Attrition was higher in studies with shorter reporting periods, leading to monthly weighted mean attrition rates of 3.3%/mo, 1.9%/mo, and 1.6%/month for studies reporting to 6, 12, and 24 months, respectively, and suggesting that overall patient retention may be overestimated in the published reports. In sensitivity analyses, estimated retention rates ranged from 24% in the worse case to 77% in the best case at the end of 2 y, with a plausible midpoint scenario of 50%. Conclusions Since the inception of large-scale ART access early in this decade, ART programs in Africa have retained about 60% of their patients at the end of 2 y. Loss to follow-up is the major cause of attrition, followed by death. Better patient tracing procedures, better understanding of loss to follow-up, and earlier initiation of ART to reduce mortality are needed if retention is to be improved. Retention varies widely across programs, and programs that have achieved higher retention rates can serve as models for future improvements.

[1]  E. Delaporte,et al.  Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  C. Dye,et al.  Global tuberculosis control: surveillance planning financing. WHO report 2003. , 2003 .

[3]  T. Flanigan,et al.  Lessons learned from use of highly active antiretroviral therapy in Africa. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[5]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[6]  L. Myer,et al.  Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. , 2006, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[7]  Max Essex,et al.  Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana , 2003, Journal of acquired immune deficiency syndromes.

[8]  L. Myer,et al.  Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  I. Thior,et al.  Initial Response to Highly Active Antiretroviral Therapy in HIV-1C-Infected Adults in a Public Sector Treatment Program in Botswana , 2005, Journal of acquired immune deficiency syndromes.

[10]  D. Hamer,et al.  No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. , 2005, AIDS.

[11]  L. Ivers,et al.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Ngare,et al.  Antiretroviral Durability and Tolerability in HIV-Infected Adults Living in Urban Kenya , 2007, Journal of acquired immune deficiency syndromes.

[13]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[14]  G. Harms,et al.  Risk factors for treatment denial and loss to follow‐up in an antiretroviral treatment cohort in Kenya , 2007, Tropical medicine & international health : TM & IH.

[15]  A. Hardon,et al.  Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa , 2007, AIDS care.

[16]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[17]  W. Miller,et al.  Lessons Learned From a Paying Antiretroviral Therapy Service in the Public Health Sector at Kamuzu Central Hospital, Malawi , 2006, Journal of the International Association of Physicians in AIDS Care.

[18]  T. F. Rinke de Wit,et al.  Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited Settings: Clinical Results From 4 African Countries , 2007, Journal of acquired immune deficiency syndromes.

[19]  Saad B Omer,et al.  Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults , 2006, Journal of acquired immune deficiency syndromes.

[20]  P. Narciso,et al.  One year of HAART in Mozambique: survival, virological and immunological results of DREAM project in Adults and Children , 2004 .

[21]  A. Mocroft,et al.  Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. , 1997, International journal of epidemiology.

[22]  Anthony D Harries,et al.  Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. , 2006, Bulletin of the World Health Organization.

[23]  B. Marston,et al.  A Program to Provide Antiretroviral Therapy to Residents of an Urban Slum in Nairobi, Kenya , 2007, Journal of the International Association of Physicians in AIDS Care.

[24]  I. Buchan,et al.  Adherence to HAART : A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006 .

[25]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[26]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[27]  G. Guyatt,et al.  Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. , 2006, JAMA.

[28]  L. Myer,et al.  Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design , 2005, AIDS.

[29]  S. Lawn,et al.  How can earlier entry of patients into antiretroviral programs in low-income countries be promoted? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  C. Mahé,et al.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? , 2002, AIDS.

[31]  J. Saba,et al.  Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire , 2003, AIDS.

[32]  N. Ford,et al.  Scaling up HIV testing in resource-constrained settings: Debates on the role of VCT and Routine ‘Opt-in or Opt-out’ HIV Testing , 2005 .

[33]  E. Delaporte,et al.  Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study , 2006, AIDS.

[34]  B. Strom,et al.  Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector , 2006, AIDS.

[35]  P. Burkhart,et al.  Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[36]  L. Kumaranayake,et al.  Evaluation of a workplace HIV treatment programme in South Africa , 2007, AIDS.

[37]  Charles Kabugo,et al.  Long-Term Experience Providing Antiretroviral Drugs in a Fee-for-Service HIV Clinic in Uganda: Evidence of Extended Virologic and CD4+ Cell Count Responses , 2005, Journal of acquired immune deficiency syndromes.

[38]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[39]  E. Schouten,et al.  True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. , 2007, Bulletin of the World Health Organization.

[40]  Kara Wools-Kaloustian,et al.  Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.

[41]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[42]  A. Harries,et al.  Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.